DS-2243a not checked

Daiichi Sankyo

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Escalation Part: DS-2243a will be administered at escalating doses to determine the RDE Expansion Part: DS-2243a will be administered at RDE”In the company’s words, NCT06644755 on ClinicalTrials.gov
Tested for
Solid Tumors, Sarcoma
Main trialPhase 1
“This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.”In the company’s words, NCT06644755 on ClinicalTrials.gov

Other drugs for Solid Tumors

All 2440 drugs for Solid Tumors

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 30 Nov 2028 First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow DS-2243a

Following is part of Solo: you see every change to DS-2243a the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in